ClinicalTrials.gg
RecruitingNCT07578571Updated Nov 3, 2026

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

A Phase 1 interventional study of IM-1617 in Colorectal Cancer, Non-Small Cell Lung Cancer and Breast Cancer, sponsored by Immunome, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Immunome, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 3, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
517th of 1,932
200 · median 64
Started
2026
with 117 others
Phase 1
551 of 2,339
100 open now
Primary completion
2029-01
later than 510 of 628 live
Registered
2,285th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 517th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 118 that started in 2026, is one of 551 in phase 1, reaches primary completion later than 510 of the 628 other live ones, and was the 2,285th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.

Read the detailed description

This is a Phase 1 open-label, multicenter, dose escalation and expansion study designed to determine the safety, tolerability, PK, and preliminary antitumor activity of IM-1617 administered to participants with unresectable locally advanced or metastatic solid tumors. The study consists of 2 parts:

Part A: A dose-escalation phase to evaluate the safety and tolerability of IM-1617 to determine the recommended dose for expansion (RDE), evaluate maximum tolerated dose, and maximum achievable dose of IM-1617.

Part B: An expansion phase to further evaluate the safety and preliminary antitumor activity of IM-1617 monotherapy at the RDE and one or more other dose regimens in up to 4 indication-specific cohorts.

03

Conditions studied

  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Esophageal Cancer
  • Stomach Cancer
  • Cancer
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0, 1, or 2
  2. Part A: Histological diagnosis of one of the following unresectable locally advanced or solid tumors:

    • CRC, all subtypes
    • NSCLC:

      • Non-squamous cell carcinoma subtypes, such as adenocarcinoma
      • Squamous cell carcinoma subtype
    • Breast cancer (subtypes based on estrogen/progesterone receptor and testing according to American Society of Clinical Oncology - College of American Pathologists guidelines):

      • Triple-negative breast cancer
      • HR+, HER2- subtype
    • Esophageal, esophagogastric junction, and gastric cancer:

      • Adenocarcinoma subtype
    • Other histologies, if approved by the Medical Monitor, which may include: head and neck squamous cell carcinoma; cervical cancer; bladder cancer; squamous cell carcinoma subtype of esophageal, esophagogastric junction, and gastric cancer; HER2+ breast cancer
  3. Part B Cohorts - Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:

    • Cohort B1: CRC, all subtypes
    • Cohort B2: NSCLC

      • Non-squamous cell carcinoma subtypes, such as adenocarcinoma
      • Squamous cell carcinoma subtype
    • Cohorts B3 and B4: Cohort-specific disease indications may include those listed for Part A
  4. Participants must have disease that is considered to be noncurative and meet the appropriate criteria below:

    • Part A only: Participants have progressed on, were intolerant to, or have a to prior SOC treatments, with no satisfactory SOC treatment options available.
    • Part B only:

      • Cohort B1 (CRC):

        • Participants must have previously progressed on, were intolerant to, or have a contraindication to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, bevacizumab, and for those with RAS wild-type tumors, an anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibody in advanced disease setting.
        • Participants with actionable biomarkers must have been treated with at least one prior appropriate biomarker-directed therapy.
        • If any of these therapies were given in the setting, disease must have progressed within 6 months after completing therapy.
        • Participants must not have received more than 3 (excluding targeted therapies for actionable biomarkers).
      • Cohort B2 (NSCLC):

        • Participants must have previously progressed on, were intolerant to, or have a contraindication to platinum-based chemotherapy and a programmed cell death-1 ()/programmed death ligand 1 (PD-L1) monoclonal antibody (given concurrently or sequentially with chemotherapy) in advanced disease setting.
        • Participants with actionable biomarkers must have been treated with at least one prior appropriate targeted therapy.
        • If any of these therapies were given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
        • Participants must not have received more than 2 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
      • Cohorts B3 and B4: Criteria will be specified based on the disease indications selected.
  5. Participants must have as defined per v1.1

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with an antibody-drug conjugate (ADC) with a topoisomerase-1 (TOP1) inhibitor payload. Exception: Participants with NSCLC or breast cancer may have received up to one prior ADC with a TOP1 inhibitor payload
  2. History of anaphylactic reaction to TOP1 inhibitors (e.g., irinotecan) or TOP1 inhibiting ADCs
  3. \< 12 weeks
  4. Prior solid organ transplant
  5. Symptomatic ascites or pleural effusion
  6. Known active central nervous system (CNS) and/or carcinomatous meningitis
  7. Known history of another primary solid or hematologic (other than that under study), unless the participant has undergone definitive/curative therapy, has had no evidence of recurrence and has negligible risk of metastatic disease of death, with approval by the Medical Monitor
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    IM-1617 Dose Escalation

    IM-1617 given into the vein (IV; intravenously)

    Drug: IM-1617

  • Experimental
    IM-1617 Monotherapy Dose Expansion

    IM-1617 given into the vein (IV; intravenously)

    Drug: IM-1617

Interventions

  • DrugIM-1617

    IM-1617 is an antibody-drug conjugate

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs)

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  2. Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs of interest (AEIs)

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  3. Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs leading to discontinuation

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  4. Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of death

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

Secondary outcomes

  1. Characterize the PK of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by area under the concentration-time curve (AUC)

    Pharmacokinetic (PK) parameter

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  2. Characterize the PK of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by maximum observed concentration (Cmax)

    PK parameter

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  3. Characterize the PK of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by time to maximum observed concentration (Tmax)

    PK parameter

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  4. Characterize the PK of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by trough concentration (Ctrough)

    PK parameter

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  5. Characterize the immunogenicity of IM-1617

    Incidence of antidrug antibodies (ADA)

    Time frame: Through 30 days after last dose of study treatment; approximately 12 months

  6. Evaluate the preliminary antitumor activity of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors

    Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator

    Time frame: From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months

  7. Evaluate the preliminary antitumor activity of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors

    Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator

    Time frame: From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2029, 32 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 32 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
May 21, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • MD Anderson Cancer Center · Houston, United States
Nov 3, 2026
Enrollment
175→200
Nov 3, 2026
Eligibility
2 inclusion criteria edited, 2 added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedIf any of these therapies waswere given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
  • AddedParticipants must not have received more than 3 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
  • EditedIf any of these therapies waswere given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
  • AddedParticipants must not have received more than 2 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
Exclusion criteria
  • EditedKnown history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially definitive/curative therapy with, has had no evidence of recurrence for at least 2 years and approvedhas negligible risk of metastatic disease of death, with approval by the Medical Monitor
Nov 3, 2026
Secondary outcomes
1 removed, 1 description edited
What changed in the outcomes
  • RemovedEvaluate the preliminary antitumor activity of IM-1617 in participants with unresectable locally advanced or metastatic solid tumorsTime frame: From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months
  • DescriptionEvaluate the preliminary antitumor activity of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors#2: how it is measured was reworded
Nov 3, 2026
Contact
Study contact's phone or email changed: I•••@immunome.com→i•••@immunome.com. See the current contact
Sep 29, 2026
Show all 2 updates
  1. Nov 3, 2026
    1 site added
    Show site
    • MD Anderson Cancer Center · Houston, United States
    Enrollment 175→200
    Eligibility 2 inclusion criteria edited, 2 added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedIf any of these therapies waswere given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
    • AddedParticipants must not have received more than 3 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
    • EditedIf any of these therapies waswere given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
    • AddedParticipants must not have received more than 2 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
    Exclusion criteria
    • EditedKnown history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially definitive/curative therapy with, has had no evidence of recurrence for at least 2 years and approvedhas negligible risk of metastatic disease of death, with approval by the Medical Monitor
    Secondary outcomes 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedEvaluate the preliminary antitumor activity of IM-1617 in participants with unresectable locally advanced or metastatic solid tumorsTime frame: From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months
    • DescriptionEvaluate the preliminary antitumor activity of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors#2: how it is measured was reworded
    + 2 other changes: verification date and description
  2. Sep 29, 2026
    Contact Study contact's phone or email changed: I•••@immunome.com→i•••@immunome.com. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07578571
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
May 11, 2026
Start date
May 21, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Immunome Medical Monitor
Contact
info@immunome.com
800-811-4074

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion